Drug intelligence / Profile preview

1C008-DM1

Development stage: Preclinical
Lead developer: Trans Chromosomics
Modality: Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics
Administration: Intravenous

Overview

**1C008-DM1** is an experimental, fully human **EpCAM-targeted antibody-drug conjugate** generated by covalently coupling the human anti-EpCAM monoclonal-antibody clone 1C008 to the maytansinoid payload DM1 using an Fc-directed affinity peptide-based chemical conjugation method. The construct was evaluated in vitro against EpCAM-expressing HCT116 human colon cancer cells and showed the greatest cytotoxicity among the tested anti-EpCAM DM1 conjugates. It is a published preclinical research construct, not an approved medicine or registered clinical-stage asset. ([pmc.ncbi.nlm.nih.gov](https://pmc.ncbi.nlm.nih.gov/articles/PMC10015092/))

Targets

EPCAM (Epithelial cell adhesion molecule)TUBB (Tubulin (alpha and beta subunits))

Beyond the preview

Go deeper on 1C008-DM1.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on 1C008-DM1.

Explore the full profile